GLP-1's Are Everywhere

Your labs say normal. But you don't feel normal. There's a reason for that… and it's fixable.

Kora MD® is the first GLP-1 and Peptide brand that pairs you with a real U.S. physician who actually looks at the full picture: hormones, metabolism, inflammation, and everything standard care misses - and who’s with you on your entire journey - at no extra cost.

No waiting rooms. 100% online. All 50-states. And your own clinical partner who knows you, your goals, and your journey.

👉 Get Your Free Consultation Today

Hey ,

There is no medication class that has dominated the health conversation over the last three years the way GLP-1 receptor agonists have.

Ozempic.
Wegovy.
Mounjaro.

These names are household words now.

And the conversation around them has been almost entirely binary: either a miracle that renders diet and exercise optional, or a shortcut for people who should just try harder.

Both framings miss the point entirely.

What is GLP-1?

GLP-1 is not a pharmaceutical invention. It is a hormone your body produces naturally in response to eating, signaling the pancreas to release insulin, slowing gastric emptying, and telling your brain you're full.

In a metabolically healthy individual, this works efficiently. In individuals with insulin resistance and metabolic dysfunction, which describes the majority of American adults, GLP-1 signaling is frequently impaired. The satiety signal is blunted, and the appetite brake doesn't work the way it should.

GLP-1 receptor agonists restore a regulatory function that metabolic dysfunction has compromised. That context changes the entire conversation.

What The Research Shows

The weight loss outcomes are real. Semaglutide produces average losses of 15% of body weight in clinical trials. Tirzepatide approaches 20-22% in some trials. Both outcomes dwarf anything previously available in non-surgical obesity treatment.

But weight loss is not the most important finding in the GLP-1 literature.

The SELECT trial, published in the New England Journal of Medicine in 2023, demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in individuals with obesity and established cardiovascular disease, independent of weight loss. There appears to be a direct cardioprotective mechanism operating separately from the scale.

GLP-1 agonists also improve insulin sensitivity, reduce visceral fat, lower triglycerides, reduce systemic inflammation, slow kidney disease progression, and reduce non-alcoholic fatty liver disease. Emerging research is examining GLP-1 receptor activity in the brain in the context of Alzheimer's, Parkinson's, and addiction.

This pharmacological profile is remarkable.

And yet, it’s almost entirely absent from the public conversation.

What The Conversation is Missing

Muscle loss is a serious concern. Research indicates that approximately 40% of the weight lost on GLP-1 medications can be lean mass rather than fat. Muscle is your metabolic engine. Losing it accelerates insulin resistance and reduces metabolic rate, directly undermining the long-term outcomes these medications are supposed to support. This is not an argument against GLP-1s, but it is an argument for using them within a protocol that includes resistance training and adequate protein intake.

Stopping without a plan produces predictable outcomes. Weight regain after discontinuing GLP-1 medications is significant and common when underlying metabolic dysfunction hasn't been addressed.

These are powerful tools, not a permanent fix in the absence of the metabolic work that addresses root causes.

Unsupervised use is a genuine safety issue. The FDA has raised explicit concerns about fraudulent compounded semaglutide and tirzepatide products flooding the market with inaccurate dosing, contamination risks, and no clinical oversight.

The explosion of telehealth prescribing without comprehensive metabolic assessment has produced patients on powerful medications without the monitoring or lifestyle integration that responsible use requires.

They don't work for everyone. Stanford Medicine research has identified a meaningful subset of the population that shows limited response. Blanket prescribing without individual assessment is not a strategy.

What Responsible Use Actually Looks Like

GLP-1 medications within a physician-guided metabolic protocol are genuinely powerful. The operative phrase is within a protocol.

Responsible use starts with a comprehensive metabolic assessment, not a BMI calculation and a prescription. It includes body composition analysis, hormonal and inflammatory markers, a resistance training framework to protect lean mass, regular monitoring, and a transition plan. The goal of metabolic medicine is never permanent pharmaceutical dependency. The goal is restoring metabolic function over time.

That’s a clinical conversation, and it requires a physician who understands the full picture.

My Honest Take

GLP-1 medications are not magic, and they are not a shortcut. They are a clinically significant class of metabolic drugs that, in the right patient with the right protocol, produce outcomes that were previously out of reach.

The conversation worth having isn't about the number on the scale. It's about what these medications reveal: that metabolic dysfunction is biological, measurable, and addressable. It’s also about what it takes to use them in a way that produces durable results.

At Kora MD, GLP-1 therapy is available and never prescribed in isolation. It is one tool within a physician-guided protocol built around your specific picture.

Because a medication this powerful deserves a clinical framework worthy of it.

That's the work Kora MD was built to do.

Quick Question For You:

More coming soon,

Austin L. Wright

Join my inner circle - Follow me on X for daily business breakdowns, lifestyle hacks, and a behind-the-scenes look at what my team and I are building.

Follow me on IG to see how I’m living the blueprint. I practice what I preach.

P.S.

• We’re always looking to improve and create better newsletters for you in the future. If you have any feedback or suggestions for future editions, I’d love to hear from you! Just reply directly to this email and give me some ideas for how you think we could make it better!
  

• If you’re reading this online, make sure you subscribe using the button below:

_{Disclaimer: The ideas shared in this newsletter are those of the author, and this is in no way intended to be medical, legal, or financial advice. Always do your own research and consult with licensed professionals.}